GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Other: Novel endpoint determination
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2747
- Registration Number
- NCT00292552
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
Phase 2
Completed
- Conditions
- Coronary Heart Disease
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00291902
- Locations
- 🇵🇱
GSK Investigational Site, Poznan, Poland
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
Phase 2
Completed
- Conditions
- DiphtheriaTetanusPertussisHepatitis BHib DiseasesNeisseria Meningitidis Serogroups A & C Diseases
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2006-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 525
- Registration Number
- NCT00291967
HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: Part ADrug: Part B
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 201
- Registration Number
- NCT00291928
Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.
Phase 1
Completed
- Conditions
- Tuberculosis (TB)
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00291889
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule
Phase 4
Completed
- Conditions
- Hepatitis A
- Interventions
- Biological: Havrix™
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT00291876
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Non-Insulin-Dependent Diabetes Mellitus
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00291356
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
Phase 3
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Tritanrix™- HepBBiological: Hiberix™Biological: Mencevax™ ACWY
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 296
- Registration Number
- NCT00291343
- Locations
- 🇵🇭
GSK Investigational Site, Sampaloc, Manila, Philippines
Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00291382
- Locations
- 🇸🇪
GSK Investigational Site, Lund, Sweden
Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years
Phase 4
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Mencevax ACWY
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 249
- Registration Number
- NCT00290329
- Locations
- 🇵🇭
GSK Investigational Site, Pasay City, Philippines
© Copyright 2025. All Rights Reserved by MedPath